i-Base home
Search Menu
  • Home
  • HTB
  • 2022
  • May

HTB

May 2022

Contents

Editorial

  • HTB May 2022 (2 May 2022)

Conference reports

  • 29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): third reports
  • CROI 2022: Dolutegravir plus recycled tenofovir rather than switch to AZT: public health approach to second-line ART
  • CROI 2022: Other COVID-19 studies

Antiretrovirals

  • FDA approves dispersible dolutegravir/abacavir/3TC for children
  • Access to ibalizumab uncertain in Europe: TaiMed looking for new partner after Thera quits

Coinfections and complications

  • Asymptomatic COVID-19 is common in people living with HIV
  • Longest COVID-19 infection lasted 505 days in an immunocompromised person in London
  • Herd immunity unlikely to control COVID-19: opinion article from US NIAID
  • The challenges of prioritising access to molnupiravir and nirmatrelvir–ritonavir for COVID-19
  • Increased risk of blood clots after COVID-19: higher with underlying conditions and more severe symptoms
  • Two new platform vaccines against COVID-19 report phase 3 results

HIV prevention and transmission

  • A&E adopts opt-out HIV testing in London, Manchester, Salford and Brighton
  • Zimbabwe decriminalises HIV transmission

Cure research

  • Community webinar series on HIV cure-related cell and gene therapy

Other news

  • Family of Greek activist Zak Kostopoulos decry minimal sentence given to his killers

PDFs

  • HTB: no. 5 (2 May 2022) PDF downloads
  • HTB RSS

Early access

  • HIV guidelines recommend a statin for all people older than 40: new BHIVA document 21 November 2023
  • Dolutegravir monotherapy still not recommended: 4-year follow up in early-treated durably suppressed participants 12 November 2023
  • CHAI 2023 market report: decline in HIV funding threatens 20 years of progress 2 November 2023
  • Mpox vaccines still available and recommended in the UK and US 2 November 2023
  • All early access reports

Current issues

  • November 2023
  • October 2023
  • September 2023
  • Back issues

Special report

  • Uganda report: Increase in LGBTQI+ assaults and human rights violations need urgent activist responses 1 October 2023

More from HTB

  • Conference reports
  • Conference shortcuts
  • Articles by subject
  • PDFs
  • Subscribe
  • HTB homepage

Home

  • i-Base homepage

This website sets no cookies from us or anyone else.

Information on this website is provided by treatment advocates and offered as a guide only. Decisions about your treatment should always be taken in consultation with your doctor.

HIV i-BASE
About us - Contact - Cookies and privacy - Copyright waiver - Terms of use - Home
107 The Maltings, 169 Tower Bridge Road, London SE1 3LJ.
Tel + 44 (0) 208 616 2210. Email admin@i-base.org.uk
Registered charity no: 1081905. Company reg no: 3962064.

Search i-Base

Site navigation

Quick links
HIV positive
Advocate
Professional
Donate
Feedback
Advice and information
Q and A
Phoneline
Pocket info
Guides
HIV meds
Glossary
Research and conference reports
HTB
HTB South
Pipeline report
Publications and resources
Publications
Other resources
Translations
Slide sets
Order and subscribe
News and updates
News
Blogs
Advocates' network
UK-CAB
Training manual
i-Base
About us
Contact
Sitemap
Home
Find us on Facebook
i-Base on Facebook